Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor

Background/Aims: Tryptophan is the precursor of serotonin and niacin (vitamin B-3). The latter is critical for normal cellular metabolism. Tryptophan and niacin can be deficient in patients with serotonin-producing neuroendocrine tumors (NETs). Niacin deficiency may lead to severe symptoms including pellagra. In patients with serotonin-producing NET, data on niacin status are scarce and niacin supplementation hardly receives attention. We aimed to assess the niacin status before and after supplementation in these patients. Methods: We identified serotonin-producing NET patients who had received oral niacin supplementation (mean dose 144 mg daily) for tryptophan deficiency and/or pellagra-associated symptoms. Presupplementation plasma tryptophan levels and niacin status based on the urinary niacin metabolite N-1-methylnicotinamide (N-1-MN) before (n = 42) and after the start of the supplementation (in 34 paired samples) were assessed. Reference values for urinary N-1-MN levels were established in 133 healthy individuals. Results: The mean presupplementation plasma tryptophan level was 31.8 +/- 9.7 mu mol/l (reference value 40.0-70.0). Presupplementation urinary N-1-MN levels were lower in patients (median 17.9 mu mol/24 h, range 2.6-70.3) compared to healthy controls (median 43.7 mu mol/24 h, range 9.5-169.3, p < 0.0001) and below normal in 45% of the patients. Niacin supplementation increased urinary N-1 -MN levels to high normal levels (median 55.5 mu mol/24 h, range 7.4-489.0) in 86% of the niacin-deficient patients. Conclusion: In serotonin-producing NET patients, niacin deficiency is prevalent. Therefore, urinary N-1-MN deserves to be included in their standard biochemical evaluation. Niacin supplementation normalizes the niacin status in most niacin-deficient serotonin-producing NET patients. A prospective study is warranted. (C) 2015 S. Karger AG, Basel